Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis

Affiliation auteurs!!!! Error affiliation !!!!
TitreRadiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis
Type de publicationJournal Article
Year of Publication2020
AuteursPons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Rivera S, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Goncalves A, Jankowski C, Rouge TDe la Mott, Pouget N, De La Lande B, Mouttet-Boizat D, Ferrero J-M, Uwer L, Eymard J-C, Mouret-Reynier M-A, Petit T, Courtinard C, Filleron T, Robain M, Dalenc F
JournalRADIOTHERAPY AND ONCOLOGY
Volume145
Pagination109-116
Date PublishedAPR
Type of ArticleArticle
ISSN0167-8140
Mots-cléscohort study, de novo metastatic breast cancer, Exclusive radiotherapy, Locoregional treatment, Propensity score
Résumé

{Background: The impact of locoregional treatment (LRT) on overall survival (OS) in de novo metastatic breast cancer (dnMBC) is still under debate, with very few data available regarding exclusive radiotherapy (ERT) as a therapeutic modality. Methods: We evaluated the impact of ERT, exclusive surgery, or a combination of surgery plus radiotherapy (bimodality therapy, BMT) on survival outcomes in a national real-life dnMBC cohort. The primary and secondary end points were OS and progression free survival (PFS) according to LRT (ERT, exclusive surgery, BMT) and no LRT. Sensitivity analyses were performed using propensity score matched analyses. Results: From 2008 to 2014, 4507 dnMBC patients were identified. Only patients alive and free from progression under systemic therapy at least 1 year after diagnosis were included (n = 1965). Forty-five percent of patients (891/1965) underwent LRT: 41.1% (n = 366) ERT, 13.7% (n = 122) exclusive surgery, and 45.2% (n = 403) BMT. OS adjusted for major prognostic factors was significantly longer in the ERT and BMT group compared with no-LRT group, but not exclusive surgery (hazard ratio (HR) = 0.63, 95% confidence interval (CI) [0.49, 0.80], p < 0.001
DOI10.1016/j.radonc.2019.12.019